TNFSF10 and B-cell chronic lymphocytic leukemia: DAC inhibitors possessing class I inhibitory activity have shown the potential to sensitize many types of tumor cells [33], [34], including CLL [35], to tumor necrosis factor-related apoptosis inducing ligand (TRAIL).